Nogra Pharma Limited
Records under this name other than the patents Nogra Pharma Limited holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 21 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,133,099 | Compounds and Their Salts Specific to the Ppar Receptors and the Egf Receptors and Their Use in the Medical Field Term ended Term ended Jul 24, 2026 · Medium confidence | Term ended | Term ended Jul 24, 2026 | Medium confidence |
| US 9,345,680 | Compounds and their salts specific to the PPAR receptors and the EGF receptors and their use in the medical field Term ended Ended no later than Jul 24, 2026 · From the USPTO record | Term ended | Ended no later than Jul 24, 2026 | From the USPTO record |
| US 9,561,202 | Compounds and their Salts Specific to the PPAR Receptors and the EGF Receptors and their Use in the Medical Field Term ended Term ended Jul 24, 2026 · High confidence | Term ended | Term ended Jul 24, 2026 | High confidence |
| US 10,016,381 | Compounds and Their Salts Specific to the Ppar Receptors and the Egf Receptors and Their Use in the Medical Field Lapsed on the fee record Ended Jul 10, 2026 · Medium confidence | Lapsed on the fee record | Ended Jul 10, 2026 | Medium confidence |
| US 8,710,100 | Compounds and Their Salts Specific to the Ppar Receptors and the Egf Receptors and Their Use in the Medical Field Formerly held Lapsed on the fee record Ended Apr 29, 2026 · Medium confidence | Lapsed on the fee record | Ended Apr 29, 2026 | Medium confidence |
| US 9,913,817 | Methods for preventing or reducing colon carcinogenesis Lapsed on the fee record Ended Mar 13, 2026 · From the USPTO record | Lapsed on the fee record | Ended Mar 13, 2026 | From the USPTO record |
| US 11,162,097 | Methods of Treating Intestinal Fibrosis Using SMAD7 Inhibition Formerly held Lapsed on the fee record Ended Nov 2, 2025 · High confidence | Lapsed on the fee record | Ended Nov 2, 2025 | High confidence |
| US 9,682,050 | Methods of treating lactose intolerance Lapsed on the fee record Ended Jun 20, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 20, 2025 | From the USPTO record |
| US 10,959,970 | Methods of treating hair related conditions Lapsed on the fee record Ended Mar 30, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 30, 2025 | From the USPTO record |
| US 8,153,693 | Compounds for the selective treatment of the intestinal immuno-inflammatory component of the celiac disease Lapsed on the fee record Ended Apr 10, 2024 · From the USPTO record | Lapsed on the fee record | Ended Apr 10, 2024 | From the USPTO record |